HK1208380A1 - 苯乙酸前藥的治療監測方法 - Google Patents

苯乙酸前藥的治療監測方法

Info

Publication number
HK1208380A1
HK1208380A1 HK15109202.8A HK15109202A HK1208380A1 HK 1208380 A1 HK1208380 A1 HK 1208380A1 HK 15109202 A HK15109202 A HK 15109202A HK 1208380 A1 HK1208380 A1 HK 1208380A1
Authority
HK
Hong Kong
Prior art keywords
methods
phenylacetic acid
therapeutic monitoring
acid prodrugs
prodrugs
Prior art date
Application number
HK15109202.8A
Other languages
English (en)
Inventor
Bruce Scharschmidt
Masoud Mokhtarani
Original Assignee
Horizon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49380684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1208380(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Horizon Therapeutics Inc filed Critical Horizon Therapeutics Inc
Publication of HK1208380A1 publication Critical patent/HK1208380A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806Determination of free amino acids
    • G01N33/6812Assays for specific amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
HK15109202.8A 2012-04-20 2015-09-18 苯乙酸前藥的治療監測方法 HK1208380A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636256P 2012-04-20 2012-04-20
PCT/US2012/054673 WO2013158145A1 (en) 2012-04-20 2012-09-11 Methods of therapeutic monitoring of phenylacetic acid prodrugs

Publications (1)

Publication Number Publication Date
HK1208380A1 true HK1208380A1 (zh) 2016-03-04

Family

ID=49380684

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15109202.8A HK1208380A1 (zh) 2012-04-20 2015-09-18 苯乙酸前藥的治療監測方法
HK18103625.7A HK1243959A1 (zh) 2012-04-20 2018-03-15 苯乙酸前藥的治療性檢測方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18103625.7A HK1243959A1 (zh) 2012-04-20 2018-03-15 苯乙酸前藥的治療性檢測方法

Country Status (25)

Country Link
US (4) US9561197B2 (zh)
EP (2) EP2846791B1 (zh)
JP (3) JP6234436B2 (zh)
KR (2) KR102264579B1 (zh)
CN (3) CN104540507A (zh)
AU (3) AU2012377389A1 (zh)
BR (1) BR112014026138A2 (zh)
CL (2) CL2014002807A1 (zh)
CY (1) CY1118838T1 (zh)
DK (1) DK2846791T3 (zh)
EC (1) ECSP14024561A (zh)
ES (2) ES2623470T3 (zh)
HK (2) HK1208380A1 (zh)
HR (1) HRP20170651T1 (zh)
HU (1) HUE032726T2 (zh)
IL (2) IL235127A (zh)
LT (1) LT2846791T (zh)
MX (1) MX365302B (zh)
PL (1) PL2846791T3 (zh)
PT (1) PT2846791T (zh)
RS (1) RS55870B1 (zh)
SG (2) SG11201406745VA (zh)
SI (1) SI2846791T1 (zh)
WO (1) WO2013158145A1 (zh)
ZA (1) ZA201407597B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2629859T3 (es) 2011-09-30 2017-08-16 Horizon Therapeutics, Llc Fármacos para eliminar nitrógeno para su uso en un procedimiento para tratar un trastorno de retención de nitrógeno
CN104540507A (zh) 2012-04-20 2015-04-22 海波龙治疗公司 苯乙酸前药的治疗性监测方法
LT2922576T (lt) * 2012-11-21 2018-02-12 Horizon Therapeutics, Llc Azotą surišančių vaistų, skirtų kepenų encefalopatijos gydymui, skyrimo ir įvertinimo būdai
RS59429B1 (sr) 2013-10-14 2019-11-29 Immedica Pharma Ab Postupci tretmana poremećaja ciklusa uree
ES2748294T3 (es) * 2014-06-04 2020-03-16 Immedica Pharma Ab Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
US20190076383A1 (en) * 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
DE69612755T2 (de) 1995-02-07 2001-08-23 Brusilow Entpr Llc Triglyceride und ethylester von phenylalkansäuren und phenylalkensäuren zur behandlung verschiedener erkrankungen
US6219567B1 (en) 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20050273359A1 (en) 2004-06-03 2005-12-08 Young David E System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure
ES2537974T3 (es) 2004-11-26 2015-06-16 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para el tratamiento de la encefalopatía hepática
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US20070004805A1 (en) 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
WO2007059031A2 (en) 2005-11-10 2007-05-24 Massachusetts Institute Of Technology Methods and compositions for raising levels and release of gamma aminobutyric acid
US8094521B2 (en) 2007-02-28 2012-01-10 Nightingale Products LLC Caregiver personal alert device
GB2451259B (en) * 2007-07-25 2011-07-20 Gp Acoustics Loudspeaker
CA2711807A1 (en) 2008-01-08 2009-07-16 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
PL3133396T3 (pl) 2008-04-29 2019-03-29 Horizon Therapeutics, Llc Sposób leczenia z zastosowaniem leków wychwytujących amoniak
WO2010025303A1 (en) * 2008-08-29 2010-03-04 Hyperion Therapeutics Dosing and monitoring patients on nitrogen-scavenging drugs
ES2695534T3 (es) * 2008-08-29 2019-01-08 Horizon Therapeutics Llc Métodos de tratamiento usando fármacos de captación de amoniaco
WO2011011781A1 (en) 2009-07-24 2011-01-27 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
JP6049619B2 (ja) 2010-08-31 2016-12-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ナノヒドロキシアパタイトを含む多孔質多糖足場、及び骨形成のための使用
ES2629859T3 (es) 2011-09-30 2017-08-16 Horizon Therapeutics, Llc Fármacos para eliminar nitrógeno para su uso en un procedimiento para tratar un trastorno de retención de nitrógeno
CN104540507A (zh) * 2012-04-20 2015-04-22 海波龙治疗公司 苯乙酸前药的治疗性监测方法
LT2922576T (lt) 2012-11-21 2018-02-12 Horizon Therapeutics, Llc Azotą surišančių vaistų, skirtų kepenų encefalopatijos gydymui, skyrimo ir įvertinimo būdai

Also Published As

Publication number Publication date
ZA201407597B (en) 2017-05-31
RS55870B1 (sr) 2017-08-31
HRP20170651T1 (hr) 2017-06-30
KR20190116552A (ko) 2019-10-14
WO2013158145A1 (en) 2013-10-24
JP2018039830A (ja) 2018-03-15
JP2015514757A (ja) 2015-05-21
HUE032726T2 (en) 2017-10-30
DK2846791T3 (en) 2017-03-27
US9561197B2 (en) 2017-02-07
EP2846791B1 (en) 2017-02-08
IL235127A (en) 2017-12-31
HK1243959A1 (zh) 2018-07-27
WO2013158145A9 (en) 2014-05-01
BR112014026138A2 (pt) 2017-06-27
US20170266143A1 (en) 2017-09-21
PT2846791T (pt) 2017-05-25
JP6637941B2 (ja) 2020-01-29
US20180263938A1 (en) 2018-09-20
IL255918B (en) 2019-06-30
AU2019201811B2 (en) 2020-07-09
EP3222275B1 (en) 2020-06-24
MX2014012694A (es) 2015-06-03
CL2014002807A1 (es) 2015-02-27
AU2018200163A1 (en) 2018-02-01
SG11201406745VA (en) 2014-12-30
SI2846791T1 (sl) 2017-06-30
KR102264579B1 (ko) 2021-06-11
MX365302B (es) 2019-05-29
AU2018200163B2 (en) 2018-12-20
CY1118838T1 (el) 2018-01-10
AU2019201811A1 (en) 2019-04-04
ES2623470T3 (es) 2017-07-11
JP6234436B2 (ja) 2017-11-22
CL2017001375A1 (es) 2018-01-05
SG10201608749UA (en) 2016-12-29
EP3222275A1 (en) 2017-09-27
JP2019219413A (ja) 2019-12-26
US20180015058A1 (en) 2018-01-18
PL2846791T3 (pl) 2017-07-31
AU2012377389A1 (en) 2014-10-30
EP2846791A1 (en) 2015-03-18
IL255918A (en) 2018-01-31
EP2846791A4 (en) 2015-08-19
CN113995743A (zh) 2022-02-01
CN111991383A (zh) 2020-11-27
KR20150013170A (ko) 2015-02-04
LT2846791T (lt) 2017-04-10
ECSP14024561A (es) 2015-09-30
CN104540507A (zh) 2015-04-22
ES2807951T3 (es) 2021-02-24
US20130281530A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
HRP20190420T1 (hr) Postupci proizvodnje akrilne kiseline
HK1243959A1 (zh) 苯乙酸前藥的治療性檢測方法
HK1209793A1 (zh) 檢測疾病或病狀的方法
HK1205697A1 (zh) 含有羥基的藥物的前藥
EP2802381A4 (en) PHOTOTHERAPY SURVEILLANCE
GB201110403D0 (en) Monitoring of conduits
HK1216361A1 (zh) 電池組件系統
HK1199095A1 (zh) 用於監測對抗 療法的反應性的方法
EP2817531A4 (en) MONITORING BRAKES
EP2866854A4 (en) METHODS OF USING POLYMERS
HK1197230A1 (zh) 環氧化二十碳三烯酸類似物、其製備方法及其應用
EP2745235A4 (en) METHOD FOR REPOSITIONING MEDICATION
GB201111396D0 (en) Monitoring of livestock
PL2934134T3 (pl) Zastosowania inhalacji kwasem acetylosalicylowym
EP2888227A4 (en) NEW PRODRUGS AND METHODS OF USE
IL236965B (en) Derivatives of 5-aminolevulinic acid and uses thereof
GB201220155D0 (en) Method of manufacture
GB2506475B (en) Parameter setting method of tire monitor
HK1214587A1 (zh) 肉桂酰胺衍生物
ZA201500488B (en) Manufacture of wheels
EP2782902A4 (en) DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
ZA201308320B (en) Epoxyeicosatrienoic acid analogs and methods of making and using the same
GB201105944D0 (en) Resuscitation monitoring system